CAMP-dependent protein kinase
From Proteopedia
(Difference between revisions)
| Line 30: | Line 30: | ||
*PKA catalytic subunit binary complex | *PKA catalytic subunit binary complex | ||
| - | **[[2cpk]], [[1ctp]], [[1fmo]], [[1l3r]], [[1xh4]], [[1xh5]], [[1xh6]], [[1xh7]], [[1xh8]], [[1xh9]], [[1xha]], [[3fjq]], [[4dg0]], [[4dg2]], [[4dh1]], [[4dh3]], [[4dh5]], [[4dh7]], [[4dh8]], [[4hpt]], [[4hpu]] – mPKA + peptide inhibitor<br /> | + | **[[2cpk]], [[1ctp]], [[1fmo]], [[1l3r]], [[1xh4]], [[1xh5]], [[1xh6]], [[1xh7]], [[1xh8]], [[1xh9]], [[1xha]], [[3fjq]], [[4dg0]], [[4dg2]], [[4dh1]], [[4dh3]], [[4dh5]], [[4dh7]], [[4dh8]], [[4hpt]], [[4hpu]], [[4xw6]], [[4xw5]], [[4xw4]], [[3x2w]], [[3x2v]], [[3x2u]] – mPKA + peptide inhibitor<br /> |
**[[1q61]], [[1q62]], [[1smh]], [[2qur]], [[3qal]], [[3qam]], [[4dfx]], [[4dfz]], [[4dg3]] - mPKA (mutant) + peptide inhibitor<br /> | **[[1q61]], [[1q62]], [[1smh]], [[2qur]], [[3qal]], [[3qam]], [[4dfx]], [[4dfz]], [[4dg3]] - mPKA (mutant) + peptide inhibitor<br /> | ||
**[[4iac]], [[4iad]], [[4iaf]], [[4iai]], [[4iak]], [[4iay]], [[4iaz]], [[4ib0]], [[4ib1]], [[4ib3]], [[4o22]] – mPKA + SP20 peptide<br /> | **[[4iac]], [[4iad]], [[4iaf]], [[4iai]], [[4iak]], [[4iay]], [[4iaz]], [[4ib0]], [[4ib1]], [[4ib3]], [[4o22]] – mPKA + SP20 peptide<br /> | ||
**[[4ntt]] – mPKA (mutant) + ADP<br /> | **[[4ntt]] – mPKA (mutant) + ADP<br /> | ||
| - | **[[2gfc]], [[3dnd]], [[3dne]], [[3kkv]], [[3zo1]], [[3zo2]], [[3zo3]], [[3zo4]], [[4ie9]], [[4ij9]] - bPKA + peptide inhibitor<br /> | + | **[[2gfc]], [[3dnd]], [[3dne]], [[3kkv]], [[3zo1]], [[3zo2]], [[3zo3]], [[3zo4]], [[4ie9]], [[4ij9]], [[4yxs]], [[4yxr]] - bPKA + peptide inhibitor<br /> |
**[[4wih]] - PKA + peptide inhibitor – hamster<br /> | **[[4wih]] - PKA + peptide inhibitor – hamster<br /> | ||
**[[2gng]], [[4axa]], [[4c33]], [[4c34]], [[4c35]], [[4c36]], [[4c37]], [[4c38]] - bPKA (mutant) + peptide inhibitor<br /> | **[[2gng]], [[4axa]], [[4c33]], [[4c34]], [[4c35]], [[4c36]], [[4c37]], [[4c38]] - bPKA (mutant) + peptide inhibitor<br /> | ||
| - | **[[3mvj]], [[3oog]], [[3poo]], [[3vqh]] - hPKA + peptide inhibitor<br /> | + | **[[3mvj]], [[3oog]], [[3poo]], [[3vqh]], [[5j5x]], [[5izj]], [[5izf]], [[5bx7]], [[5bx6]], [[4ujb]], [[4uja]], [[4uj9]], [[4uj2]], [[4uj1]] - hPKA + peptide inhibitor<br /> |
| + | **[[4z84]], [[4z83]] - hPKA (mutant) + peptide inhibitor<br /> | ||
**[[4wb5]], [[4wb6]], [[4wb8]] – mPKA (mutant) + PKI peptide<br /> | **[[4wb5]], [[4wb6]], [[4wb8]] – mPKA (mutant) + PKI peptide<br /> | ||
**[[3bwj]] - bPKA + bisubstrate inhibitor<br /> | **[[3bwj]] - bPKA + bisubstrate inhibitor<br /> | ||
| Line 53: | Line 54: | ||
**[[1jbp]] - mPKA + detergent + peptide inhibitor + ADP<br /> | **[[1jbp]] - mPKA + detergent + peptide inhibitor + ADP<br /> | ||
**[[1rdq]] - mPKA + peptide inhibitor + ADP + ATP<br /> | **[[1rdq]] - mPKA + peptide inhibitor + ADP + ATP<br /> | ||
| + | **[[4o21]] - mPKA + peptide inhibitor + ATP-γ-S<br /> | ||
**[[1atp]] - mPKA + peptide inhibitor + Mn-ATP<br /> | **[[1atp]] - mPKA + peptide inhibitor + Mn-ATP<br /> | ||
**[[2erz]] - mPKA + peptide inhibitor + hydroxyfasudil<br /> | **[[2erz]] - mPKA + peptide inhibitor + hydroxyfasudil<br /> | ||
| Line 62: | Line 64: | ||
**[[3nx8]] - hPKA catalytic subunit + peptide inhibitor + phenol<br /> | **[[3nx8]] - hPKA catalytic subunit + peptide inhibitor + phenol<br /> | ||
**[[3l9m]], [[3l9n]], [[3ama]], [[3amb]] - hPKA (mutant) + peptide inhibitor + inhibitor<br /> | **[[3l9m]], [[3l9n]], [[3ama]], [[3amb]] - hPKA (mutant) + peptide inhibitor + inhibitor<br /> | ||
| + | **[[3wyg]] – hPKA + GSP1P + exportin<br /> | ||
**[[3ow3]] - mPKA catalytic subunit + peptide inhibitor + inhibitor<br /> | **[[3ow3]] - mPKA catalytic subunit + peptide inhibitor + inhibitor<br /> | ||
**[[2f7e]], [[2f7x]], [[2f7z]], [[2jds]] - bPKA catalytic subunit + peptide inhibitor + inhibitor<br /> | **[[2f7e]], [[2f7x]], [[2f7z]], [[2jds]] - bPKA catalytic subunit + peptide inhibitor + inhibitor<br /> | ||
| Line 89: | Line 92: | ||
**[[2drn]], [[2h9r]] - rPKA II-α dimerization-anchoring domain + A-kinase anchoring protein peptide – NMR<br /> | **[[2drn]], [[2h9r]] - rPKA II-α dimerization-anchoring domain + A-kinase anchoring protein peptide – NMR<br /> | ||
| - | **[[2izx]], [[2izy]] - hPKA II-α + A-kinase anchoring protein peptide<br /> | + | **[[2izx]], [[2izy]], [[4zp3]] - hPKA II-α + A-kinase anchoring protein peptide<br /> |
**[[3im4]] - bPKA I-α + A-kinase anchoring protein peptide<br /> | **[[3im4]] - bPKA I-α + A-kinase anchoring protein peptide<br /> | ||
**[[2hwn]] - rPKA II-α + A-kinase binding peptide<br /> | **[[2hwn]] - rPKA II-α + A-kinase binding peptide<br /> | ||
| Line 96: | Line 99: | ||
**[[2kyg]] - hPKA II-α + CBFA2T1<br /> | **[[2kyg]] - hPKA II-α + CBFA2T1<br /> | ||
**[[3plq]] - bPKA I-α + cAMP derivative<br /> | **[[3plq]] - bPKA I-α + cAMP derivative<br /> | ||
| + | **[[5t3n]] - PfPKA + cAMP derivative – ''Plasmodium falciparum''<br /> | ||
| + | **[[5kbf]], [[5k8s]] - PfPKA + cAMP <br /> | ||
*PKA regulatory subunit ternary complex | *PKA regulatory subunit ternary complex | ||
| Line 103: | Line 108: | ||
*PKA catalytic and regulatory subunits | *PKA catalytic and regulatory subunits | ||
| - | **[[2qvs]], [[3idb]], [[3idc]], [[3pvb]], [[4din]] - mPKA <br /> | + | **[[2qvs]], [[3idb]], [[3idc]], [[3pvb]], [[4din]], [[4x6q]], [[4wbb]] - mPKA <br /> |
| - | **[[3fhi]], [[2qcs]], [[3tnp]], [[3tnq]] - mPKA (mutant) <br /> | + | **[[3fhi]], [[2qcs]], [[3tnp]], [[3tnq]], [[4x6r]] - mPKA (mutant) <br /> |
**[[3j4q]], [[3j4r]] – mPKA + A-kinase anchor protein 18<br /> | **[[3j4q]], [[3j4r]] – mPKA + A-kinase anchor protein 18<br /> | ||
| + | **[[5jr7]] – m+bPKA + ADP<br /> | ||
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 09:30, 23 March 2017
| |||||||||||
3D structures of cAMP-dependent protein kinase
Updated on 23-March-2017
References
- ↑ Bastidas AC, Wu J, Taylor SS. Molecular Features of Product Release for the PKA Catalytic Cycle. Biochemistry. 2014 Aug 8. PMID:25077557 doi:http://dx.doi.org/10.1021/bi500684c
- ↑ Brown SH, Cheng CY, Saldanha SA, Wu J, Cottam HB, Sankaran B, Taylor SS. Implementing Fluorescence Anisotropy Screening and Crystallographic Analysis to Define PKA Isoform-Selective Activation by cAMP Analogs. ACS Chem Biol. 2013 Sep 10. PMID:23978166 doi:10.1021/cb400247t
